Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective

Bone

Volumn 59, Issue , 2014, Pages 105-113

  Parthan, A ^a   Kruse, M ^a   Agodoa, I ^b   Silverman, S ^c   Orwoll, E ^d  

^a OPTUM   (United States)

^b AMGEN INC   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cost effectiveness; Denosumab; Fracture; Male osteoporosis; Sweden

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; GENERIC DRUG; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; ELDERLY CARE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH STATUS; HIP FRACTURE; HUMAN; MALE; MORTALITY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SENSITIVITY ANALYSIS; SPINE FRACTURE; STATISTICAL MODEL; SWEDEN; TREATMENT DURATION; VERY ELDERLY;

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO COMPARE THE EFFICACY AND SAFETY OF DENOSUMAB 60MG EVERY SIX MONTHS VERSUS PLACEBO IN MALES WITH OSTEOPOROSIS; ADAMO; BMD; BONE MINERAL DENSITY; COST-EFFECTIVENESS; DAPS; DENOSUMAB; DENOSUMAB ADHERENCE PREFERENCE SATISFACTION; EMA; EQ-5D; EUROPEAN MEDICAL AGENCY; EUROQOL-5 DIMENSION; FIT; FRACTURE; FRACTURE INTERVENTION TRIAL; FRACTURE REDUCTION EVALUATION OF DENOSUMAB IN OSTEOPOROSIS EVERY 6MONTHS; FREEDOM; HALT; HORMONE ABLATION BONE LOSS TRIAL; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; INTRAVENOUS; IV; LIFE-YEAR; LONG-TERM CARE INSTITUTION; LTC; LY; MALE OSTEOPOROSIS; MOP; NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE; NICE; PMO; POST-MENOPAUSAL OSTEOPOROSIS; PROBABILISTIC SENSITIVITY ANALYSIS; PSA; QALY; QUALITY-ADJUSTED LIFE-YEAR; SWEDEN;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INCIDENCE; MALE; MARKOV CHAINS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS; SWEDEN; TREATMENT OUTCOME;

EID: 84889568828     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.11.002     Document Type: Article

References (59)

1. Strom O., Borgstrom F., Zethraeus N., Johnell O., Lindgren L., Ponzer S., et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 2008, 79:269-280.
2. Ringe J.D., Farahmand P., Faber H., Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 2009, 29:311-315.
3. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995.
4. Strom O., Borgstrom F., Kanis J.A., Compston J., Cooper C., McCloskey E.V., et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2011, 6:59-155.
5. Kaufman J.-M., Orwoll E., Goemaere S., San Martin J., Hossain A., Dalsky G.P., et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
6. Orwoll E., Ettinger M., Weiss S., Miller P., Kendler D., Graham J., et al. Alendronate for the treatment of osteoporosis in men. NEJM 2000, 343:604-610.
7. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. NEJM 2009, 361:756-765.
8. Orwoll E., Teglbjaerg C.S., Langdahl B.L., Chapurlat R., Czerwinski E., Kendler D.L., et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012, 97:3161-3169.
9. Jonsson B., Strom O., Eisman J.A., Papaioannou A., Siris E.S., Tosteson A., et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011, 22:967-982.
10. Parthan A., Deflin M.M., Yurgin N., Huang J., Taylor D.C. Cost-effectiveness of denosumab versus oral bisphosphonates in the United States for post-menopausal osteoporosis (PMO). Value Health 2012, 15:1-256.
11. ADAMO trial data. Data on file - Amgen.
12. Orwoll E.S., Binkley N.C., Lewiecki E.M., Gruntmanis U., Fries M.A., Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010, 46:970-976.
13. Kaufman J.-M., Audran M., Bianchi G., Braga V., Diaz-Curiel M., Francis R.M., et al. Efficacy and safety of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int 2012, 23:S260.
14. Actonel (risedronate sodium) prescribing information http://www.actonel.com/global/prescribing_information.pdf.
15. Majima T., Shimatsu A., Komatsu Y., Satoh N., Fukao A., Ninomiya K., et al. Efficacy of risedronate in Japanese male patients with primary osteoporosis. Intern Med 2008, 47:717-723.
16. EMEA Committee for medicinal products for human use. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis 2006, EMEA.
17. Boonen S., Reginster J.Y., Kaufman J.M., Lippuner K., Zanchetta J., Langdahl B., et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. NEJM 2012, 367:1714-1723.
18. Landfeldt E., Strom O., Robbins S., Borgstrom F. Adherence to treatment of primary osteoporosis and its association to fractures - the Swedish Adherence Register Analysis (SARA). Osteoporos Int 2011, 23:433-443.
19. Freemantle N., Satram-Hoang S., Tang E.-T., Kaur P., Macarios D., Siddhanti S., et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012, 23:317-326.
20. Ziller V., Kostev K., Kyvernitakis I., Boeckhoff J., Hadji P. Persistence and compliance of medications used in the treatment of osteoporosis - analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012, 50:315-322.
21. Tamone C., Fonte G., Panico A., Molinatti P.A., D'Amelio P., Isaia G.C. Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment. Calcif Tissue Int 2012, 90:272-278.
22. Kanis J.A., Oden A., Johnell O., Jonsson B., de Laet C., Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001, 12:417-427.
23. Hasserius R., Karlsson M.K., Nilsson B.E., Redlund-Johnell I., Johnell O. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 2003, 14:61-68.
24. Swedish life tables http://www.Mortality.org.
25. Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., et al. Mortality after osteoporotic fractures. Osteoporos Int 2004, 15:38-42.
26. Kanis J.A., Oden A., Johnell O., de Laet C., Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004, 15:108-112.
27. Poor G., Atkinson E.J., O'Fallon W.M., Melton L.J. Determinants of reduced survival following hip fractures in men. Clin Orthop 1995, 319:260-265.
28. Kanis J. Excess mortality after vertebral fracture 2002, WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield, UK.
29. Parker M.J., Anand J.K. What is the true mortality of hip fractures?. Public Health 1991, 105:443-446.
30. Kanis J.A., Oden A., Johnell O., de Laet C., Jonsson B., Oglesby A.K. The components of excess mortality after hip fracture. Bone 2003, 32:468-473.
31. Haentjens P., Magaziner J., Colon-Emeric C.S., Vanderschueren D., Milisen K., Velkeniers B., et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010, 152:380-390.
32. Burstrom K., Johannesson M., Diderichsen F. A comparison of individual and social time trade-off values for health states in the general population. Health Policy 2006, 76:359-370.
33. Peasgood T., Herrmann K., Kanis J.A., Brazier J.E. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 2009, 20:853-868.
34. Kanis J.A., Johnell O., Oden A., Borgstrom F., Zethraeus N., De Laet C., et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004, 15:20-26.
35. Borgstrom F., Jonsson B., Strom O., Kanis J.A. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006, 17:1781-1793.
36. Zethraeus N., Strom O.E., Borgstrom F. What is the risk of institutionalization after hip fracture?. Osteoporos Int 2006, 17:S184.
37. National Institute for Health and Clinical Excellence (UK) Systematic reviews of clinical effectiveness prepared for the guideline osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk September 2008, National Collaborating Centre for Nursing and Supportive Care, [Available at http://www.nice.org.uk/guidance/index.jsp?action=download&o=42362].
38. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. NEJM 2007, 357:1799-1809.
39. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM 2007, 356:1809-1822.
40. Strom O., Borgstrom F., Sen S.S., Boonen S., Haentjens P., Johnell O., et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007, 18:1047-1061.
41. Borgstrom F., Johnell O., Kanis J.A., Oden A., Sykes D., Jonsson B. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004, 22:1153-1165.
42. Schousboe J.T., Taylor B.C., Fink H.A., Kane R.L., Cummings S.R., Orwoll E.S., et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007, 298:629-637.
43. Huybrechts K.F., Ishak K.J., Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006, 38:922-928.
44. Solomon D.H., Avorn J., Katz J.N., Finkelstein J.S., Arnold M., Polinski J.M., et al. Compliance with osteoporosis medications. Arch Intern Med 2005, 165:2414-2419.
45. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Miller P.D., Yang Y.C., et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011, 96:972-980.
46. Prince R., Sipos A., Hossain A., Syversen U., Ish-Shalom S., Marcinowska E., et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005, 20:1507-1513.
47. Kanis J.A., Adams J., Borgstrom F., Cooper C., Jonsson B., Preedy D., et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008, 42:4-15.
48. Liu H., Michaud K., Nayak S., Karpf D.B., Owens D.K., Garber A.M. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006, 166:1209-1217.
49. Kanis J.A., Reginster J.Y., Kaufman J.M., Ringe J.D., Adachi J.D., Hiligsmann M., et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 2012, 23:213-221.
50. Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. NEJM 2009, 361:745-755.
51. Boonen S., Adachi J.D., Man Z., Cummings S.R., Lippuner K., Torring O., et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011, 96:1727-1736.
52. McClung M.R., Boonen S., Torring O., Roux C., Rizzoli R., Bone H.G., et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2011, 10.1002/jbmr.536.
53. Inderjeeth C.A., Foo A.C.H., Lai M.M.Y., Glendenning P. Efficacy and safety of pharmacological agents in managing osteoporosis in the old: review of the evidence. Bone 2009, 44:744-751.
54. Boonen S., Black D.M., Colon-Emeric C.S., Eastell R., Magaziner J.S., Eriksen E.F., et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010, 58:292-299.
55. Seeman E., Vellas B., Benhamou C., Aguino J.P., Semler J., Kaufman J.M., et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006, 21:1113-1120.
56. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
57. http://www.skane.se.
58. http://www.fass.se.
59. http://www.apoteket.se.